Metropolis Healthcare, under the leadership of Ameera Shah, has introduced TruHealth Cancer Screen 360, a comprehensive cancer screening solution aimed at boosting preventive oncology efforts across India. This innovative panel includes gender-specific diagnostic profiles and hereditary risk analysis, enabling early cancer detection in both urban and rural regions.

The screening panel features Male and Female Profiles, carefully designed to deliver early diagnostic insights. It includes a multi-layered testing approach with tumour markers, organ-specific assessments, and hereditary cancer risk evaluation using a 317-gene NextGen Panel. The platform supports screening for over 25 cancer types, including breast, cervical, ovarian, liver, lung, prostate, colorectal, and thyroid cancers.

India currently faces a major cancer burden, with low screening rates—under 1% for cervical, breast, and oral cancers—far below the WHO’s 70% target. TruHealth Cancer Screen 360 addresses this gap with accessible, affordable, and evidence-based diagnostics. Features like HPV self-sampling kits for women and free genetic counselling make it more user-friendly and informative.

According to Metropolis CEO Surendran Chemmenkottil and Dr. Kirti Chadha, the tool empowers early diagnosis and improved health outcomes. The launch aligns with the company’s vision to extend advanced diagnostic services nationwide, especially in oncology.

Offered at an introductory, cost-effective price, the TruHealth Cancer Screen 360 is part of Metropolis’ mission to integrate cancer screening into routine healthcare and reduce late-stage diagnoses.